JNJ’s Q2 Results Reaffirm Our Stance For Pharmaceutical Growth
Johnson & Johnson (NYSE: JNJ) posted Q2 results on July 19th, 2016. Company’s Pharmaceutical division continues to show strong growth. JNJ stock price has been through a rally over past month, cresting over our price estimate of $119 to reach $125. Here are the reasons we believe JNJ may continue to show strong growth.
Have more questions about Johnson & Johnson? See the links below.
- Drugs, Devices, Consumer: What’s Johnson & Johnson’s Revenue and Earnings breakdown?
- How Increased Focus On Pharmaceuticals In The Last 5 Years Has Helped J&J?
- By How Much Can J&J’s Revenue And EBITDA Grow Over The Next 3 Years?
- What Percentage Of Its Revenue Could J&J Lose Solely Due To Patent Losses Over The Next 5 Years?
- If Remicade Biosimilar Hits The U.S. Market In 2017, Does J&J Face Any Meaningful EPS Decline?
- Considering Recent Divestitures, Should J&J Trim Its Medical Devices Segment Further?
- Despite The Revenue Fall, J&J’s Business Has A Silver Lining
- Three Things To Watch Out For J&J This Year
- Here Is Why J&J Could See Growth As It Reports Its Q1 2016 Results
- Why We Are Slightly Bullish On J&J?
- What’s Next For Johnson & Johnson Stock After Beating Q1 Earnings?
- Here’s What To Expect From Johnson & Johnson’s Q1
- What’s Next For Johnson & Johnson Stock After A 6% Decline In A Month?
- Is Johnson & Johnson Stock A Better Pick Over AbbVie?
- Will Johnson & Johnson Stock Rebound To Its Pre-Inflation Shock Highs of $185?
- Should You Pick Johnson & Johnson Stock At $160?
Notes:
See More at Trefis | View Interactive Institutional Research (Powered by Trefis)